⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL439647 | 0.74 | — | — | |
| SCHEMBL27952255 | 0.73 | PIK3CB (0.41) | — | |
| SCHEMBL11250319 | 0.73 | — | — | |
| SCHEMBL25428969 | 0.73 | — | — | |
| SCHEMBL20611026 | 0.73 | — | — | |
| SCHEMBL23128404 | 0.73 | — | — | |
| SCHEMBL31227892 | 0.73 | — | — | |
| SCHEMBL15032488 | 0.72 | KDM5A (0.35) | — | |
| SCHEMBL12884843 | 0.72 | KDM4E (0.34) | — | |
| Iodide SCHEMBL29172953 | 0.71 | PIK3CB (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230037255-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LTD (IE) | 2023-02-02 | — | — | US | disclosed |
| US-20220389031-A1 | MACROCYCLIC SULFONYLAMIDE DERIVATIVES USEFUL AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2022-12-08 | — | — | US | disclosed |
| US-11370776-B2 | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors | INFLAZOME LIMITED (IE) | 2022-06-28 | — | — | US | disclosed |
| EP-3912984-A1 | 4'-FLUORO-NUCLEOSIDES, 4'-FLUORO-NUCLEOTIDES AND ANALOGS THEREOF FOR THE TREATMENT OF HCV | Janssen BioPharma, Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| US-20210332020-A1 | PHENYLSULFONYLUREA DERIVATIVES USEFUL AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2021-10-28 | — | — | US | disclosed |
| WO-2021043966-A1 | NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2021-03-11 | — | — | WO | disclosed |
| WO-2021032591-A1 | MACROCYCLIC SULFONYLUREA DERIVATIVES USEFUL AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2021-02-25 | — | — | WO | disclosed |
| WO-2021032588-A1 | MACROCYCLIC SULFONYLAMIDE DERIVATIVES USEFUL AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2021-02-25 | — | — | WO | disclosed |
| US-20200270227-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2020-08-27 | — | — | US | disclosed |
| EP-2697241-B1 | 1'-SUBSTITUTED PYRIMIDINE N-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES INC (US) | 2019-06-12 | — | — | EP | disclosed |
| WO-2019008025-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2019-01-10 | — | — | WO | disclosed |
| WO-2019008029-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2019-01-10 | — | — | WO | disclosed |
| EP-3421482-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Alios Biopharma, Inc. (US) | 2019-01-02 | — | — | EP | disclosed |
| US-8877733-B2 | 1′-substituted pyrimidine N-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20130149283-A1 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS | UNIVERSITA DEGLI STUDI DI CAGLIARI (IT) | 2013-06-13 | — | — | US | disclosed |
| US-20110111393-A1 | PNA Probes, Mixtures, Methods And Kits Pertaining To The Determination Of Mycoplasma and related Mollicutes | HYLDIG-NIELSEN JENS J | 2011-05-12 | — | — | US | disclosed |
| US-7910563-B2 | Antisense oligonucleotide to inhibit melanoma inhibitory activity, MIA | ANTISENSE PHARMA GMBH (DE) | 2011-03-22 | — | — | US | disclosed |
| EP-1501812-B1 | PNA MONOMER AND PRECURSOR | PANAGENE INC (KR) | 2009-12-30 | — | — | EP | disclosed |
| EP-1012267-B1 | AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD | BIOGNOSTIK GES (DE) | 2009-04-15 | — | — | EP | disclosed |
| EP-1889911-A2 | An antisense oligonucleotide preparation method | Biognostik Gesellschaft für biomolekulare Diagnostik mbH (DE) | 2008-02-20 | — | — | EP | disclosed |